Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Zimmer Biomet Holdings, Inc. (ZBH) Healthcare & Pipeline Overview

Zimmer Biomet Holdings, Inc. (ZBH) is a major player in the musculoskeletal healthcare industry, providing reconstructive and S.E.T. (sports medicine, extremities, trauma) products. With a focus on innovation and a global presence, the company serves orthopedic surgeons, neurosurgeons, and other specialists, maintaining a significant market share in orthopedics and dental solutions.

What Is the Investment Thesis for ZBH?

With a market capitalization of $17.9B and a P/E ratio of 22.38, the company demonstrates financial stability. Key value drivers include an aging global population and increasing demand for orthopedic procedures. The company's dividend yield of 1.17% offers a steady income stream. Growth catalysts include expanding its S.E.T. product line and penetrating emerging markets. However, potential risks include regulatory changes and competition from other medical device manufacturers. The company's gross margin of 70.0% and profit margin of 9.1% indicate efficient operations.

Based on FMP financials and quantitative analysis

ZBH Key Highlights

Market capitalization of $17.9B, reflecting a substantial presence in the musculoskeletal healthcare market.

• P/E ratio of 22.38, suggesting a reasonable valuation relative to earnings.
• Gross margin of 70.0%, indicating strong pricing power and efficient cost management.
• Profit margin of 9.1%, showcasing the company's ability to convert revenue into profit.
• Dividend yield of 1.17%, providing a steady income stream for investors.

Who Are ZBH's Competitors?

ZBH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ZBH's Key Strengths?

Strong market position in the orthopedic industry.

• Comprehensive product portfolio.
• Global distribution network.
• Commitment to research and development.

What Are ZBH's Weaknesses?

Exposure to regulatory changes and healthcare reforms.

• Dependence on reimbursement rates from insurance providers.
• Potential for product recalls and liability claims.
• Intense competition in the medical device market.

What Could Drive ZBH Stock Higher?

New product launches in the knee and hip replacement segments, driving revenue growth.

• Expansion into emerging markets, such as China and India, increasing market share.
• Strategic partnerships and acquisitions to expand product portfolio and geographic reach.
• Positive clinical trial results for new biologics and regenerative medicine products.
• Increasing demand for minimally invasive surgical procedures.

What Are the Key Risks for ZBH?

Regulatory changes and healthcare reforms impacting reimbursement rates.

• Intense competition from other medical device manufacturers.
• Product liability lawsuits and recalls.
• Economic downturns and reduced healthcare spending.
• Supply chain disruptions affecting manufacturing and distribution.

What Are the Growth Opportunities for ZBH?

• Expansion of S.E.T. (Sports Medicine, Extremities, and Trauma) Product Line: Zimmer Biomet can capitalize on the growing demand for sports medicine and trauma-related products. The global sports medicine market is projected to reach $11.8 billion by 2028. By expanding its S.E.T. product line, Zimmer Biomet can increase its market share and revenue. This includes developing innovative products for minimally invasive procedures and focusing on biologics for tissue regeneration.
• Penetration of Emerging Markets: Emerging markets, such as China and India, offer significant growth opportunities for Zimmer Biomet. These markets have a large and growing population with increasing access to healthcare. By expanding its presence in these markets, Zimmer Biomet can tap into a new customer base and increase its revenue. This includes establishing local manufacturing facilities and developing products tailored to the needs of these markets.
• Innovation in Robotic Surgery: Zimmer Biomet can leverage the growing trend of robotic surgery to enhance its product offerings and improve patient outcomes. The global surgical robotics market is projected to reach $14.7 billion by 2027. By developing robotic-assisted surgical systems for orthopedic procedures, Zimmer Biomet can attract surgeons and hospitals looking for advanced surgical solutions. This includes integrating robotics with its existing implant portfolio.
• Development of Personalized Implants: Zimmer Biomet can focus on developing personalized implants tailored to the specific needs of each patient. This includes using 3D printing technology to create custom implants that match the patient's anatomy. Personalized implants can improve surgical outcomes and patient satisfaction. The market for personalized implants is expected to grow as technology advances and costs decrease.
• Strategic Acquisitions and Partnerships: Zimmer Biomet can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. This includes acquiring companies with complementary technologies or products and partnering with distributors to enter new markets. Strategic acquisitions and partnerships can accelerate Zimmer Biomet's growth and strengthen its competitive position.

What Are ZBH's Competitive Advantages?

• Strong brand reputation and established market presence in the orthopedic industry.
• Extensive product portfolio covering a wide range of musculoskeletal conditions.
• Significant investment in research and development, leading to innovative products and technologies.
• Global distribution network and established relationships with healthcare providers.
• Intellectual property protection through patents and trademarks.

What Does ZBH Do?

Zimmer Biomet Holdings, Inc. was founded in 1927 in Warsaw, Indiana, and has since grown into a global leader in the musculoskeletal healthcare sector. The company's evolution has been marked by strategic acquisitions and a commitment to innovation in orthopedic reconstructive products. Zimmer Biomet designs, manufactures, and markets a comprehensive range of products, including knee and hip implants, sports medicine devices, biologics, and spine products. These products are used in a variety of surgical procedures to treat patients suffering from disorders or injuries to bones, joints, or supporting soft tissues. The company also offers dental reconstructive implants and other dental products. Zimmer Biomet's geographic reach extends across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its products are sold to orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, and other healthcare providers. Zimmer Biomet competes with other major players in the orthopedic device market, focusing on product innovation, customer service, and global expansion to maintain its competitive edge. The company changed its name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc. in June 2015, reflecting its expanded product portfolio and market presence following the merger with Biomet.

What Products and Services Does ZBH Offer?

• Designs, manufactures, and markets orthopedic reconstructive products.
• Offers knee and hip replacement implants.
• Provides sports medicine, biologics, foot and ankle, extremities, and trauma products (S.E.T.).
• Develops and markets spine products, including medical devices and surgical instruments.
• Offers face and skull reconstruction products.
• Provides dental reconstructive implants and related products.
• Offers robotic, surgical, and bone cement products.

How Does ZBH Make Money?

• Develops and manufactures a wide range of musculoskeletal healthcare products.
• Sells products directly to hospitals, surgeons, and other healthcare providers.
• Utilizes a network of distributors and agents to reach customers in various geographic markets.
• Generates revenue through the sale of implants, surgical instruments, and related products.

What Industry Does ZBH Operate In?

Zimmer Biomet operates in the medical device industry, specifically focusing on musculoskeletal healthcare. The industry is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging global population. The market is competitive, with key players like STERIS plc (STE) and others vying for market share. Zimmer Biomet's focus on innovation and a comprehensive product portfolio positions it well to capitalize on industry growth trends. The global orthopedic device market is expected to continue growing, driven by factors such as rising obesity rates and increasing sports-related injuries.

Who Are ZBH's Key Customers?

• Orthopedic surgeons
• Neurosurgeons
• Oral surgeons and dentists
• Hospitals and healthcare facilities
• Healthcare purchasing organizations

Company Profile

Zimmer Biomet Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Warsaw, US. The company is led by CEO Ivan Tornos. ZBH has traded publicly since 2001.

Zimmer Biomet Holdings, Inc. Financial Trajectory

Zimmer Biomet Holdings, Inc. (ZBH) reported $2.18B in revenue for Q2 FY2026, reflecting 4.3% growth compared to the prior quarter. The company recorded net income of $198.3M, with diluted EPS of $1.03. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ZBH averaged $1.03 in diluted EPS.

How Zimmer Biomet Holdings, Inc. Is Valued

Zimmer Biomet Holdings, Inc. carries a market capitalization of $17.9B, placing it in the large-cap category. Analyst price targets span from $93.00 to $120.00, with a consensus of $103.11. At the current price of $92.44, that implies approximately 12% upside potential. Relative to its peer group, ZBH's quantitative score of 78/100 is roughly in line with the peer average of 70/100.

Return on equity for Zimmer Biomet Holdings, Inc. stands at 6.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. ZBH trades at a trailing price-to-earnings ratio of 22.38, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 10.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.

Zimmer Biomet Holdings, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.45 places it in the grey zone, a middle ground that warrants monitoring.

Zimmer Biomet Holdings, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.2% above estimates on average.

Over the past six months, Zimmer Biomet Holdings, Inc. insiders filed 44 SEC Form 4 transactions — 7 sales and 37 purchases. On net that is roughly 31K shares acquired (about $224K) — insiders putting money in tends to read as conviction.

ZBH Financials

ZBH Latest News

ZBH Analyst Consensus

ZBH MoonshotScore

Common Questions About ZBH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources